Logo | Name | Σ | Employees |
---|---|---|---|
![]() | MedXCell SA The Cell Therapy Venture Builder MedXCell is a European cell therapy venture builder with a strong industrial mindset and a global perspective. Our focus is on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders. Established in 2018, we have offices in Switzerland, the EU (France) and the US (Cambridge, MA) and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development and funding capabilities. Biotechnology, Cell Therapy, Immunotherapy, NK Cells, Mesenchymal Stromal Cells, Immuno-oncology, and Osteoarthritis 410 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 9 |
![]() | ![]() Combining human and machine intelligence to discover the next generation of therapeutic antibodies. LabGenius Therapeutics ("LabGenius") is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company’s discovery platform, EVATM, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. While EVATM is both modality and format-agnostic, LabGenius' internal pipeline is focussed on the development of selectivity-enhanced antibodies for the treatment of solid tumours. The company's novel approach is delivering a pipeline of antibody therapeutics with best-in-class killing profiles. Medical, Health, and DNA Libraries 61 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: A.I. Robotics Synthetic Biology A.I. - Machine Learning | 17 | 68 |
![]() | ![]() Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. We have developed a pipeline of ‘off-the-shelf’ vaccines which induce immune responses and highly tumour specific monoclonal antibodies that redirect immune cells or drugs. Our advanced therapeutic vaccine programmes, SCOPE and ModiFY, have shown promising efficacy in Phase 2 trials, demonstrating long-term survival in metastatic melanoma and … Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology | 0 | 59 |
![]() | ![]() Preventing deaths from cancer metastases Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, we are empowering the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high efficiency vectors and intelligent clinical trial design. Our mission is to significantly enhance patient survival. 293 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 35 |
![]() | ![]() Guiding clinicians towards personalized treatment and enhancing quality of life for patients Using molecular structures to choose the best therapy. Currently focusing on mutations in EGFR and other lung cancer drivers. Working closely with the Molecular Tumor Board at the UMCG #umcg and patient organizations across Europe. 61 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology | 2 | 13 |
![]() | ![]() Building a pipeline of immuno-therapies to fight against cancer and multiresistant pathogens ALPIONER Therapeutics is a biotech company developing new generation of immunotherapies against cancer and multi-resistant pathogens. Its aT3-plaform is leveraging a bacterial secretion system to inject high quantity of peptides or functional proteins, into the cytosol of the host cell. ALP-102 is a first-in-class vaccine candidate targeting Pa infections while ALP-201-neo is neoantigen-based personnalized cancer vaccine. 67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 18 | 3 |
![]() | ![]() Delivering the promise of immunotherapy Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body. The company is currently developing a pipeline of drug candidates consisting of OncoMimicsTM peptide-based immunotherapies for the treatment of cancer. EO2463 is in a Phase 2 clinical trial for indolent non-Hodgkin lymphoma, demonstrating a benign … 61 similar entities Tags: FrenchTech2030 Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology | 15 | 47 |
![]() | ![]() Going beyond treatment, striving for cures Cycuria Therapeutics is a preclinical-stage oncology startup based in Graz, Austria, founded by scientists from the Medical University of Graz, TU Munich and the University of Heidelberg. We are pioneering a novel protein-based targeted therapy for hematological cancers and beyond. Our approach selectively targets tumor and tumor stem cells while preserving healthy hematopoiesis and overall physiology. This enables durable efficacy without dose-limiting toxicity, as demonstrated in preclinical animal models and patient-derived disease models. By combining excellent tolerability with long-lasting efficacy, our novel therapeutic strategy aims to address significant unmet needs in cancer treatment, offering … Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 6 |
![]() | ![]() Pioneering A New Class of Universal Vaccines Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1200 subjects tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company … 54 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 25 | 58 |
![]() | ![]() Versatile immunotherapy for personalized cancer medicine Inovactis develops an innovative treatment against cancer at the border between several ongoing revolutions: individualized medicine, immunotherapy and synthetic biology. personalized immunotherapy and medicine 98 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 1 |
![]() | ![]() #biopharma #biotech #drugdiscovery #GPCR #Immunooncology #inflammation Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and … 24 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 25 | 81 |
![]() | ![]() Valerio is a clinical-stage biotechnology company developing novel oncology drugs targeting tumor DNA-binding functions. Valerio Therapeutics is a clinical-stage biotechnology company based in France and the US that develops new drugs by targeting tumor DNA functions through unique mechanisms of action in the field of DNA Damage Response (DDR). DDR consists of a network of cellular pathways that detect, report and repair DNA damage. Applied to oncology, this new field of research aims to weaken or block the ability of tumor cells to repair damage to their DNA, either naturally or under the effect of cytotoxic treatments. Focusing exclusively on … 25 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology | 1 | 49 |
![]() | ![]() Plant-based Nanotechnologies for autoimmune diseases diagnoses and therapy DIAMANTE (Nano-Technologies for Autoimmune Disease) is a biotech company focused on the use of plants for producing high value-added molecules. The company was funded in 2016 with the development of new tools in autoimmune disease diagnosis and now we are growing approaching therapeutics applications. As an innovation-oriented female company, our value proposition is the creation of novel therapeutic approach for autoimmune diseases based on the restoration of self-tolerance, using plant viruses displaying immunodominant peptides. Diamante, thanks to the Regione Veneto and particularly though the national grant POR FESR AZIONE 1.1.1 2020/2021, has … 52 similar entities Type: Startup Activities: nanotech biotech deeptech healthtech Technologies: Synthetic Biology | 0 | 19 |
![]() | ![]() Cancer profiling for precision oncology and early cancer detection iCellate develops and provides cancer profiling services for precision oncology. iCellate’s CellMate® is a next generation circulating tumor cell (CTC)-based platform for cancer cell detection and comprehensive biomarker analysis. GeneMate® is an analysis for hereditary cancer and gBRCA testing. Cancer Diagnostics, Circulating Tumor Cells (CTC), Liquid Biopsy, Next Generation Sequencing, CDx, Hereditary Cancer, Early Detection, Cancer, and Solid Tumors 52 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 8 |
![]() | ![]() Immunotherapy against senescence StarkAge Therapeutics is a privately-held biotechnology start-up, whose ambition is to delay or halt disease progression and improve quality of life of patients with age-related diseases, associated with senescent cells accumulation. It builds on its unique disease-specific exosomal / EV technology while harnessing immunotherapy approach, to address very large senescence unmet medical needs. 70 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 3 | 11 |
![]() | ![]() Next-generation cancer treatment bringing the immune system one step ahead of cancer 🧬🟣 Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide. We developped a next-generation cancer treatment, thanks to our “off-the-shelf” therapeutic platform. Our lead candidate is a proteomic-driven immunotherapy targetting colorectal cancer (CRC), the 2nd deadliest cancer worldwide. - Our allogeneic platform generates therapeutics that efficiently educate the immune system, with more potent, diverse and novel targets than any existing therapies. (Characterized by advanced multiomics technologies) - We overcome limitations of … 157 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology | 39 | 20 |
![]() | ![]() Biology x AI-powered drug development platform to transform precision oncology. Orakl Oncology leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With our platform we partner with oncology players to identify relevant targets and deliver new drugs, faster. 61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology Data Analytics | 32 | 20 |
![]() | ![]() Immuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for Patients OSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). • Tedopi® (therapeutic cancer vaccine): Registration Phase 3 in 2nd-line NSCLC in HLA-A2+ patients with secondary resistance. Phase 2 trials, sponsored by onco groups, of Tedopi® in combo in solid tumors. • Lusvertikimab (mAb IL-7R antagonist); Positive Phase 2 in UC; preclinical research in ALL. • OSE-279 (anti-PD1): 1st positive results in Phase 1/2 in solid tumors. • FR-104/VEL-101 (anti-CD28 mAb): developed in partnership with Veloxis in transplant; Phase 1/2 in renal transplant (CHU Nantes); successful Phase … 57 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 27 | 1 |
![]() | ![]() Building a sustainable sector and accelerate the discovery of new treatments tailored to each patient. French consortium to develop new experimental models of cancer in 9 cancer pathologies of interest (Lung, Pancreas, Breast, Liver, Ovary...) 3 major R&D axes: - Developing in vivo models and cell-based assays - Mimicking the human biology by humanizing the tumor microenvironment in mice - Studying the microbiota in cancer patients Oncology, Cancer research, Patient derived Xenograft, Cell lines, Ex vivo assays, Microbiota, Data mining , Translationnal medecine, Humanized mice, Biomarker, Research and Development, In vivo models, Ex vivo models, and Cancer 169 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | N/A |
![]() | ![]() 2013-2023 In a context where the rate of cancer treatment failure is still unacceptably high, our mission is to provide decision aids to oncologists. We believe that profiling is key to predicting treatment toxicity to patients and effectiveness on tumors. Over a decade of research by the French Atomic Energy Commission (CEA) on the impact of radiations on DNA has resulted in a deep understanding of the essential DNA repair mechanisms. More recently, a set of innovative biomarkers was developed that provides a complete functional signature of these mechanisms, the premise to powerful tools for personalized treatment of cancer. http://www.lxrepair.com … 63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 3 |
![]() | ![]() Developing the Weapons that we need to defeat cancer. Hephaistos-Pharma is a biotechnology startup developing anti-tumor immunotherapy to revolutionize cancer treatments by spreading the effectiveness of monoclonal antibodies and allowing the treatment of incurable tumors. Oncology, immunotherapy, and cancer 36 similar entities Type: Startup Activities: biotech deeptech | 35 | 15 |
![]() | ![]() BIOMUNEX is a biopharmaceutical company focused on the discovery and development of breakthrough immunotherapeutics BIOMUNEX Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of breakthrough immunotherapies using its Unique BiXAb® technology to create next generation bi- and multi-specific antibodies. Our disruptive biological approaches target a number of cancer types, in particular where there are unmet medical needs. We are committed to provide oncologists and patients with immunotherapies that are novel, efficacious and prolong life expectancy. 32 similar entities Type: Startup Activities: deeptech biotech | 5 | 12 |
![]() | ![]() Stromacare is a pioneer in tumoral stroma immuno-modulation and develops a therapeutic mAb for the treatment of cancers StromaCare is opening a new therapeutic avenue by targeting the tumoral Stroma, which is known to play a key role in several solid cancers, with the objective to be essential in the numerous anticancer protocols of treatment. Stromacare won the Beatrice Denys Foundation 2021 Prize (Foundation for Medical Research). The company is located in Lyon, France. oncology and monoclonal antibody 6 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 13 |
![]() | ![]() Your key partner for breakthrough antibody discovery Mabqi specializes in the discovery and development of human therapeutic antibodies. Our core technology is based on proprietary synthetic fully human libraries including pH-sensitive variants tailored for oncology applications. The company offers end-to-end discovery solutions, from antibody discovery, affinity maturation to optimization and full characterization, ensuring tailored support and delivery of high-quality and developable antibodies to meet your needs. Moreover, based on our know-how and technologies, Mabqi is committed to the discovery of therapeutic antibodies on innovative targets with off-the-shelf antibody assets available for partnered development and licensing opportunities. Antibody Discovery, Fully Human … 64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 8 | 26 |
![]() | ![]() Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune 402 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 11 | 10 |
![]() | ![]() Ready -to -use cell bank, for research, for patients Lymphobank - Bank of ready -to -use cells, for research, for patients. Lymphobank is a biotech specializing in the supply of adult and placental -use -for -use blood cells, the characteristics of which will be available online (www.lymphobank.fr), allowing the cellular product to be chosen according to an interest donor. Our services are focused on the development of cellular immunotherapy products. In addition, Lymphobank develops an innovative approach to allogenic adoptive immunotherapy of hepatocellular carcinoma (the most frequent liver cancers and second cause of cancer death in the world, with nearly … 58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 11 | 2 |
![]() | ![]() Targeting calcium signaling to cure auto-immune diseases KALSIOM is a biotech company founded in April 2020 and based in Brest, France, discovering and developing first-in-class therapies to treat auto-immunes disorders (AID) involving B-cell dysfunction with a high medical need. The company is focusing on developing first-in-class monoclonal antibodies modulating calcium-signaling pathways in lymphocytes. Immunology and Therapeutic antibodies 53 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 7 | 5 |
![]() | ![]() Chemical tools for bioconjugaison & biodrugs McSAF is a Deeptech company specialized in Bio-Organic & Bio-Conjugates Chemistry, developing innovative technologies for improved targeted therapies. Its core expertise covers Therapeutic Peptides and Proteins, Antibodies, and Drug Conjugates. The team has a strong background in synthetic selective chemistry, and a real expertise in bioconjugation, including specific designs of Antibody Drug Conjugates (ADCs) with own proprietary coupling technology. Plus, the company has now a pipeline of three products in oncology incorporating McSAF Inside technology with the ambition to bring new biodrugs on the market solving unmet medical needs. Bioconjugation, Biopharmaceuticals, Antibody Drug Conjugates, … 74 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 6 |
![]() | ![]() Memo Therapeutics AG (“MTx”) is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company’s lead program, Potravitug, is in Phase II development targeting BK viremia (BKV) in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. Potravitug has the potential to become the best and first-in-class BKV disease-modifying therapy for kidney transplant patients. Alongside Potravitug, MTx is focused on discovering novel antibody-target pairs for oncology based on tumor infiltrating B-cells derived leveraging tertiary lymphoid … 13 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 4 | 45 |
![]() | ![]() The surfaceome company. DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients. 32 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 28 |
![]() | ![]() Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer. Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer. Our mission is to develop a new drug to treat Glioblastoma Multiforme. We aim to significantly increase life expectancy for patients, improve patient comfort, and generally increase the overall survival rates for GBM patients. cancer treatments, GBM treatments, and therapeutics 58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 10 |
![]() | ![]() Next generation cell therapies for ALK-positive cancer patients At ALKemist Bio we are developing TCR-T cells that possess the ability to specifically target ALK antigens found on ALK-positive cancer cells, primarily focusing on non-small cell lung cancer patients. By harnessing the power of the immune system and engineering T cells to precisely recognize and combat these cancerous cells, we aim to pave the way for more effective treatments aiming at improving the standard of care. biotech, immunooncology, oncology, alkpositive, celltherapy, TCR, and ALK 118 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 5 |
![]() | ![]() We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases Tridek-One is a spin-off from Inserm that develops first-in-class therapeutic agonistic monoclonal antibodies targeting immune checkpoint inhibitory receptors for the treatment of autoimmune and inflammatory diseases. The company primarily focuses on the research and development of first-in-class anti-CD31 agonistic modalities designed to restore the immune balance. Anti-CD31 agonistic mAbs have the potential to provide targeted immunomodulatory activity with a favorable safety profile in diseases with high unmet clinical need. Tridek-One has initiated a discovery program which targets another ITIM receptor, fully leveraging its understanding of inhibitory checkpoint receptor … 12 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 14 |
![]() | ![]() Evexta Bio, formerly #Diaccurate, is a biopharmaceutical company exploring the new frontiers of #oncology in search of daring novel therapeutic approaches with the potential to save lives. Now in the clinic, the French biotech is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications: - Rupitasertib, formerly DIACC3010, an optimized S6K inhibitor with efficient AKT1/AKT3 control of feed-back loop. The oral anti-tumor agent is expected to enter phase 2/3 clinical trial in refractory ER+ HER2- metastatic breast cancer. - EVX020, formerly DIACC2020, an antibody-drug conjugate program using a sole-in-class KIF20A kinesin inhibitor as payload in … 74 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 6 | 9 |
![]() | ![]() Exceptional Human Antibody Discovery Technology Trianni, Inc. is a biotech company specializing in human antibody discovery platform technology. We offer the leading in vivo platform enabling efficient discovery of fully-human monoclonal antibodies. The Trianni Mouse offers biologic drug discoverers a best-in-class solution for the isolation of therapeutic antibody candidates. Benefits over older conventional mouse immunization + humanization approaches include superior lead panels with respect to potency and diversity along with speed to the clinic and lower operating costs. We aim to make Trianni’s premium technology available to any Pharma or Biotech company engaged in antibody discovery by offering flexible licenses … 46 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 1 |
![]() | ![]() Actor of change Immune Biosolutions is a clinical-stage biotechnology company specializing in the discovery and engineering of avian and human antibodies for therapeutic applications. Utilizing cutting-edge technologies, we develop custom immunotherapeutic agents. Our discovery platform efficiently targets complex proteins and generate powerful, specific, and innovative antibodies. Additionally, our antibody production capability allows us to advance our own discovery programs in cancer and autoimmune diseases into the early phases of clinical development. Anticorps, Custom antibody development, Antibody, Développement sur mesure de génération d'anticorps, IgY, Chicken, Poulet, ELISA, Therapeutic Antibodies, Recombinant Antibodies, Humanized Antibodies, GPCRs, and Oncology 91 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 6 | 23 |
![]() | ![]() Enabling our healthcare client partners to accelerate breakthrough cancer solutions. Sus Clinicals solves major problems in qualifying new cancer drugs, devices, diagnostics and therapies. Using a proprietary model of testing on genetically-modified pigs pioneered at the University of Illinois, Sus Clinicals leverages the inherent advantages of a patent-pending large animal testing methodology combined with novel clinical approaches to reduce false positives, model the interactions of multiple diseases, and accelerate progress toward human trials for the most promising therapies. 29 similar entities Type: Startup Activities: pettech deeptech biotech Technologies: Synthetic Biology | 0 | 14 |
![]() | ![]() Innovation in Marine-Derived Oncology Therapies Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin. PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other … 89 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 8 | 460 |
![]() | ![]() A lean biotech company aiming to develop revolutionary immune-based treatment for various cancers. Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to develop the next-generation of vaccines for cancer and infectious disease. With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs … 42 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 47 |
![]() | ![]() Pioneering RNA cell therapy for autoimmune disease Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systematic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com Immunotherapy, Oncology, Molecular Biology, Immunology, Myasthenia Gravis, ARDS, Cell Therapy, NETs, Gene Therapy, Cancer Research, multiple myeloma, … 59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 84 |
![]() | ![]() Transforming patients’ lives | Through world leading science | With a great team Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing an internal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development. Biotech, Oncology, and Virology 55 similar entities Type: Startup Activities: biotech deeptech | 3 | 24 |
![]() | ![]() Empower the body, cure the disease Mnemo Therapeutics is a Paris-based biotechnology company driven to create powerful immunotherapies by improving the body’s ability to detect and eradicate cancer. The paucity of actionable cancer-specific targets creates significant challenges in the field of immuno-oncology. To address this, Mnemo has developed a combination of in-silico and wet-lab pipelines to uncover new tumour-specific targets (called E-antigens) derived from the unexploited dark genome, and to develop multiple therapeutic modalities (i.e. cell therapy, TCE, ADC, vaccine) targeting these E-antigens. Mnemo is currently pursuing several discovery campaigns for E-antigens, with a plan to develop its proprietary tumour-specific … 11 similar entities Type: Startup Activities: biotech Technologies: Synthetic Biology | 6 | 28 |
![]() | ![]() Targeting protein interactions for health Founded in 2023, TheraPPI Bioscience is a biotechnology company whose science originates from the CRCL (Centre de Recherche de Cancérologie de Lyon, France). We modify protein interactions to offer treatments where current therapies fail. Our approach represents a paradigm shift in tackling cancer resistance and non-curable rare diseases protein-protein interaction, PPI, small molecule, therapeutics, oncology, and rare disease 76 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 6 |
![]() | ![]() Creating transformative medicines for patients with cancer Cytovation is a clinical stage immuno-oncology biotech developing first-in-class immunotherapies. CY-101, its lead asset, is a synthetic peptide engineered to selectively target tumor cells. CY-101 has a unique dual MoA applicable across solid tumors: (1) direct tumor-specific membrane lysis and in-situ vaccination, combined with (2) immune activation through inhibition of the β-catenin pathway. Building on strong FIH clinical data, Cytovation is advancing CY-101 to POC/pivotal clinical development with a focus on b-catenin-driven cancers. Biotech, Oncology, and Immuno-oncology 33 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 12 |
![]() | ![]() Covalab is a French biotechnology company specialized in antibody engineering, founded in 1995. We are expert in the design and development of antibody (polyclonal, monoclonal scFv, FAb, VHH, recombinant antibodies) using antigen or DNA immunization. In addition, we offer purified and labeling antibodies, peptide synthesis for research use, diagnostic and therapeuthic. As a producer, we supply many distributors to sale our innovative and high quality antibodies. Wide range of those products are available in our website. The service activity of CovalAb represents the top of the scientific and technical iceberg which the team at CovalAb has put together. Indeed, the … 44 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 6 | 21 |
![]() | ![]() Unique know-how to discover and engineer novel antibody therapeutics in immunology & inflammation (I&I) and neurology. Mabylon AG, a private Swiss biotech company, is leading innovation in antibody-based treatments for severe allergies, inflammation, and neurological disorders. Our B-cell screening platform rapidly identifies natural human antibodies with high specificity and therapeutic potential. MY006, our first-in-class multispecific antibody therapeutic for peanut allergy, is tackling the growing food allergy market. 47 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 22 |
![]() | ![]() To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies 85 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 9 |
![]() | ![]() Rebalancing the immune system, resolving inflammation. Drug candidates from our molecular platforms normalize the immune system by downregulating pro-inflammatory immune response and upregulating regulatory immune response. IMD-Pharma S.A.S is a french biotechnology company conducting research and development of innovative drug candidates for immune-related inflammatory diseases. Founded in 2016, IMD-Pharma is a company from the Laboratoire de Chimie de Coordination (CNRS) and the Centre de Physiopathologie de Toulouse Purpan (INSERM/CNRS/Université Toulouse III). immuno-modulation, anti-inflammatory drugs, chronic inflammatory diseases, Multiple Sclerosis, Rheumatoid Arthritis, dendrimers, monocyte rehabilitation, and psoriasis 46 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 7 |
![]() | ![]() Targeted imaging and therapies Zionexa is an international and innovative company developing and commercializing molecular imaging solutions, in-vivo biomarkers for targeted therapies in oncology, to improve patients’ pathway and bring them a better quality of life. Molecular Imaging, Oncology, Targeted therapies, CDx, Radiopharmaceuticals, and Biomarkers 60 similar entities Type: Startup Activities: biotech deeptech | 0 | 6 |
![]() | ![]() Innovative medicines to address haemato-oncology related life-threatening and rare diseases ElsaLys Biotech is a specialty pharmaceutical company, part of the Mediolanum Farmaceutici Spa group, focused on innovative medicines to address haemato-oncology related life-threatening and rare diseases. Following strategic acquisitions and targeted developments, ElsaLys is establishing an immunotherapeutic portfolio focused on niche specialty pharmaceuticals to answer unmet medical needs. Our commitment is to offer essential drugs meeting Public Health needs. Founded in 2013, ElsaLys Biotech is located in the heart of the European cluster Lyon Biopole, in Lyon, France. Anticorps thérapeutiques, Anticorps monoclonaux, Therapeutic antibodies, Monoclonal antibodies, ophtalmologie, immune microenvironment, vascular … 56 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 7 | 1 |
![]() | ![]() Prolonging life and increasing life quality of cancer patients through innovative immunotherapies. Learn more. Elicera Therapeutics is a clinical stage cell and gene therapy company focusing on immunooncology. The company develops CAR T-cells against both solid and liquid tumors based on its proprietary technology platform, iTANK, for a parallell activation of an innate immune response against cancer. Elicera also develops next generation oncolytic viruses with three combined mode-of-actions, applicable for treatment of most cancers. Cell and gene therapy, immunooncology, CAR T-cells, Oncolytic viruses, and immunotherapy 56 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 6 |
![]() | ![]() Multi-specific antibodies that enable the pursuit of novel therapeutic strategies. Numab Therapeutics is developing multi-specific antibody-based immunotherapies for inflammation and cancer. Reproducible plug-and-play therapeutic design process using proprietary platforms λ-CapTM and MATCHTM puts Numab in a unique position to overcome historical drug discovery barriers and build a pipeline of first-in-class and best-in-class medicines aimed to maximize patient benefits. Our lead candidate NM26, a unique multi-specific targeting IL-4/13 and IL-31 for best-in-class efficacy, is developed with a vision of delivering a lifelong cure to patients suffering from atopic dermatitis (AD) and other potential indications. Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 3 | 68 |
![]() | ![]() Transforming cancer immunotherapy with next generation ADCs Mablink Bioscience is a French biotechnology company that is actively involved in the fight against cancer by bringing disruptive therapeutic solutions. With its Antibody-Drug Conjugates (ADC) masking technology, Mablink Bioscience aims to dramatically improve the efficiency of ADC therapies and accelerate the development of new treatments. Based in Lyon, where it is developing an unprecedented innovation center, Mablink currently has around 30 employees with diverse backgrounds. biotechnology, drug development, drug discovery, oncology, and R&D 68 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 15 | 35 |
![]() | ![]() ElyssaMed® will develop the first therapeutic treatment for clinical use comprising several antigenic peptides (epitopes) derived from CTPP and selective for non-small-cell lung cancer, combined with an already marketed vaccine adjuvant. This product once administered to lung cancer patients, will amplify the patients' specific immune responses against tumor cells expressing the antigen CTPP and lead to their destruction. Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 2 |
![]() | ![]() Antibody for Therapy AbTx is a preclinical stage biotech company developing the next generation of oncology treatments to treat incurable cancers. AbTx platform is developing mAb innovative enzymatic conjugation. Our platform unlock New Frontiers in Medicine to overcome ADC major drawbacks associated targeting solid tumors by generating antibody Fragment Drug Conjugates (FDCs). ADC, Oncology, and drug develoment 69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 7 | 5 |
![]() | ![]() A drug-discovery company focused on oncology. Follow us on Twitter @OxDrugDes Oxford Drug Design, an advanced spinout from Oxford University, is an innovative biotechnology company discovering and developing novel therapeutics supported by pioneering computational methods. We design innovative drugs with differentiated modes of action against cancer and other challenging diseases with high unmet medical need seeking superior patient outcomes. Based on the unique integration of our dual core competences in aminoacyl-tRNA synthetase enzymes and distinctive AI/ML methods, our pipeline expansion is focused on oncology. This distinctive drug discovery platform has been validated by the rapid discovery of novel therapeutic candidates … 100 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology A.I. - Machine Learning A.I. | 5 | 10 |
![]() | ![]() Developing allogeneic TCR-NK therapies for solid tumors Zelluna Immunotherapy is a company pioneering the development of allogeneic T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company is developing a portfolio of tumor specific TCRs to guide NK cells with the aim to induce cancer responses that are safe, efficient and durable. For more info please visit www.zelluna.com Cancer treatment, Immunotherapy, Adoptive cell therapy, T cell receptor technologies, Immunooncology, and Solid tumors Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 30 |
![]() | ![]() A novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) PDC*line Pharma is a clinical-stage Biotechnology company that develops a new class of potent, off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line). Based on a robust preclinical package and a first-in-human phase Ib in melanoma, PDC*line Pharma reported promising Phase I/II results in lung cancer (PDC*lung) in 2024. Preparations are now underway for a randomized Phase II trial in lung cancer, and a Phase Ib trial in colorectal cancer with neoantigens (PDC*neo). The company has raised €61M … Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 13 | 25 |
![]() | ![]() The next generation of of single domain antibodies Emglev is a biotechnology company established in 2023 as a spin-off of Institut Curie dedicated to the discovery and the development of transformative immunotherapies to address unmet medical needs in oncology. By leveraging its unique proprietary platform, expertise and innovative approach, Emglev unlocks the current barriers of conventional antibody discovery to provide unique targets and sdAbs selected fully in vitro and validated for therapeutic applications in any format against any target. At Emglev Therapeutics, we have assembled an experienced, interdisciplinary team with a unique vision : to unlock the next level of … Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 3 |
![]() | ![]() New therapeutic targets based on arsenic trioxide (As2O3) Founded in 2010, MEDSENIC is a biopharmaceutical start-up that aims to exploit the new possibilities offered by the therapeutic use of arsenic trioxide (As2O3) and thereby provide a treatment for patients with autoimmune diseases. santé, biotechnologies, bioparma, biopharmaceutical, biotech, health, biotechnology, autoimmune diseases, and maladies auto-immunes 347 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 3 |
![]() | ![]() Preclinical CRO in Hematological Cancers Diag2Tec is an expert preclinical CRO devoted to hematological cancers, especially Multiple Myeloma (MM). We focused on in vitro Drug Testing in Human Hematological Cancer derived Cell Lines and Primary Cells from patients with various Hematologic Malignancies (Multiple Myeloma, Diffuse Large B Cells Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Mantle cell Lymphoma, Chronic Lymphoid Leukemia...). With our 2 platforms : Drug Testing Services and ChimioFx, our mission is to provide efficient treatment solutions for patients suffering from Hematological Malignancies with Precision Medicine approaches. We support biotech and phamaceutical companies to focus their drug development on … 26 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 9 |
![]() | ![]() Blue Bees Therapeutics develops immunomodulatory proteins with therapeutic potential to fight cancer Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG). Immunothérapie, Immuno-oncologie, pharma, Biotech, Immunologie, Oncologie, Cancer, Médicament, and Drug 176 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 8 | 9 |
![]() | In-Cell-Art In-Cell-Art, is a biopharmaceutical company specializing in the preclinical and pharmaceutical development of solutions (DNA/RNA based vaccines or therapeutics) treating acquired or inherited diseases using patented bioinspired synthetic delivery systems (named Nanotaxi®) consisting of different chemical families (lipids, polymers). Its founder and research team, which includes a Nobel Laureate, have developed this unique intellectual property expertise and know-how based on 20 years of research in the field of supramolecular nucleic acids transfection agents. The vaccines and therapeutics developed by In-Cell-Art have been validated by numerous studies using infectious disease models (HIV, Flu, Dengue, dust mite, mycobacterium abscessus), therapeutic cancer models … 35 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 1 |
![]() | ![]() World leaders in neutrophil immunotherapies to rejuvenate immune competence in solid tumours and beyond! LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media … 59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 21 |
![]() | ![]() Biology x AI-powered drug development platform to transform precision oncology. Orakl Oncology leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With our platform we partner with oncology players to identify relevant targets and deliver new drugs, faster. 61 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics Synthetic Biology | 2 | 20 |
![]() | ![]() Pioneering thymus-empowered T-cell platform to fight cancer and infection Smart Immune is a clinical-stage French biotechnology company developing ProTcell, a thymus-empowered T cell progenitor platform to fully and rapidly re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies. The company aims to radically improve outcomes for patients in hematology and immune-oncology. Smart Immune has ongoing collaborations with leading institutions in the US and Europe. SMART101 is in Phase I/II clinical trials in cancer patients with AML and ALL, in SCID in the EU and the US. Smart Immune is also developing therapies using gene-modified T … 51 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 26 | 32 |
![]() | ![]() Discovery of novel immune checkpoint inhibitors for cancer immunotherapy OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. The company was incepted in 2010 and is managed by Jeremy Bastid, CEO and Gilles Alberici, President. The science at OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our in vivo screening approach aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Our lead asset, an anti-CD39 monoclonal antibody, has been out-licensed to Innate (2016) Pharma and then partnered … 67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 6 |
![]() | ![]() Biotech company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. Tharimmune, Inc. (Nasdaq: THAR) is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors. Tharimmune has a license agreement with OmniAb, … 27 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 5 |
![]() | ![]() Developing precision small molecules to combat hard-to-treat tumors. iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families. Two therapeutic candidates have progressed into mid-stage clinical development: roginolisib is the first allosteric modulator of PI3Kδ and cambritaxestat is the only autotaxin inhibitor in clinical development to treat cancer. oncology, drug development, and clinical development 81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 9 | 33 |
![]() | ![]() Pioneering immune interventions to treat chronic disease AstriVax Therapeutics is a European based, clinical-stage biopharmaceutical company, founded in 2022, that is pioneering immune interventions to treat chronic disease. The company has two prototype prophylactic assets in clinical phase and is developing its therapeutic assets to treat chronic HBV and clear high-risk HPV. AstriVax has a novel DNA-launched viral vector immunotherapy platform, Launch-iT, that is designed to create an inherent adjuvant effect to the target antigens, eliciting durable polyfunctional CD8+ and CD4+ T cell responses and robust humoral immunity. Through Launch-iT, the company has the potential to develop best-in-class immunotherapy treatments. 85 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 36 |
![]() | ![]() UNLOCKING THE PHOSPHATASE TARGET CLASS Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications. Anavo is backed by blue-chip investors M Ventures, INKEF Capital, Taiho Ventures, and Bioqube Ventures. drug discovery, phospatase biology, and oncology 39 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 23 |
![]() | ![]() A shift in cancer treatment methodology makes a world of difference. A shift in cancer treatment methodology makes a world of difference. Oniria Therapeutics is a spin-off from Vall d'Hebron Institute of Oncology (VHIO), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA). Oniria Therapeutics is a biotech company focused on the development of first-in-class drugs in the field of precision oncology. It develops therapies to modulate and eliminate dormant tumor cells as a novel targeted strategy to overcome their persistence. Our flagship product allosterically activates TET2, a master epigenetic enzyme. Biotechnology, cancer, cell … 57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 17 |
![]() | ![]() Regenerative Medicine - Growth Disregulation - Oncology REGULAXIS is a French innovative biotechnology company based at BIOCITECH the technology park of life science of Paris North area. The company is engaged in the research, development and licensing of innovative synthetic molecules for use in human therapies. Its mission is to grant licenses of innovative molecules in a pharmaceutical company after the establishment of a phase II clinical record. REGULAXIS leads its R&D on its own premises, particularly in regard to biochemical and biological experiments, and keeps the mastery of the chemical synthesis of its therapeutic molecules. The company develops its … 250 similar entities Type: Startup Activities: biotech healthtech Technologies: Synthetic Biology | 0 | 2 |
![]() | ![]() Syndivia is committed to enhancing treatment options for cancer patients with solid tumors by leveraging the distinctive properties of targeted DAR1 antibody-drug conjugates, which offer improved tumor penetration, stability, and efficacy. Drug development, Biotechnology, Pharmaceuticals, Antibody-drug conjugates, DAR1 ADC, and ADC 155 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 7 | 6 |
![]() | ![]() Our R&D platform is focused on developing immune modulating therapeutics for patients with autoimmune diseases. Our immune checkpoint activators protect patient’s organ tissue. Unique approach : - Potential for BEST-in-class super agonist against immune-mediated tissue damage - High selectivity for active T-cells - Proof of concept in relevant human in vitro models and mouse model of disease 60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 5 |
![]() | ![]() Resolving cancer's complexity through the power of targeted drug combinations ABOUT US Mosaic Therapeutics is an oncology therapeutics company delivering precision medicines for patient groups with few targeted treatment options today. The company’s main mission is to tackle cancers with substantial unmet need by reinventing the traditional approach to target and drug discovery - leveraging our differentiated dual technology platform to advance novel combination therapies. Born out of pioneering research at the Wellcome Sanger Institute in collaboration with the Netherlands Cancer Institute, and anchored around a proprietary platform that has seen 20 years of fine-tuning and development, Mosaic has active … 158 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 26 |
![]() | ![]() Unravelling immune system function, one cell at a time Cellply is a life-science company focused on developing next-generation analytical tools enabling a deep characterization cancer immunotherapies, cell therapies and cell-based biotherapeutics. Our goal is to support the development of novel cancer immunotherapies by accelerating the R&D, advancing the quality control and monitoring the clinical response to these treatments. Through the use of proprietary microfluidic technologies, highly-automated analytical instruments and AI-powered image and data analytics, the Cellply platform defines the function of the immune system one cell at a time, combining functional data with other multiplex data and providing an unprecedented … 88 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology | 1 | 32 |
![]() | ![]() Expertise in protein engineering | in silico & in vitro antibody discovery platform We work in partnership with technology platforms, pharmaceutical companies, and academic research groups to create next generation cell and molecular therapies. We integrate novel technologies into a synthetic antibody platform to provide the most advanced discovery engine possible. 258 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 2 |
![]() | ![]() An early-stage oncology company aiming to treat solid tumors SOLID Therapeutics is an early-stage oncology company spun out of CBMR at the University of Copenhagen. We are developing novel cancer therapeutics with dual mode of action targeting both cancer cells and immune cells to treat solid tumors. 105 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 9 |
![]() | ![]() Interventional Immuno-Oncology Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their … 68 similar entities Type: Startup Activities: biotech deeptech legaltech Technologies: Synthetic Biology | 3 | 18 |
![]() | ![]() ChemoTech is a R&D based company in the field of oncology. The Company is presently marketing and selling it's IQwaveTM TSE (Tumour Specific ElectroporationTM) system which is an innovation within the field of electroporation. ChemoTech's products are presently available in Europe, India and South East Asia. The treatment is developed to treat patients with large and 'hard to treat' superficial tumours. ChemoTech's shares (CMOTEC B) are listed on NASDAQ First North in Stockholm. The Company is headquartered in Lund, Sweden. We have also a device for our Animal Care division called vetIQureTM, this device is being marketed and handled by … 13 similar entities Type: Startup Activities: biotech deeptech | 2 | 8 |
![]() | ![]() Our platform integrates biology, computation, and engineering to develop impactful antibody-based medicines. AbCellera discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. Antibody Discovery, Cell Culture, Antibody Therapies, Protein Analysis, Microfluidic Single Cell Analysis, Single Cell Genomics, Monoclonal Antibody Discovery, Cell Enrichment, Cell Screening, Cell Recovery, Protein engineering, T cell … 59 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology | 11 | 616 |
![]() | ![]() Innovative start up developing monoclonal antibodies in cancer and inflammatory diseases MImAbs is an innovative start-up specialized in immunotherapy. Our goal is to develop monoclonal antibodies in cancer and inflammatory diseases for third parties (academics, pharmacuetical companies, biotechnologies, etc.) Anticorps monoclonaux, Immuno-pharmacologie, Génération et bioproduction d'anticorps, and Génération d'immunoconjugués 113 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 4 | 35 |
![]() | ![]() Reinventing Cancer Immunotherapy Valo Therapeutics (ValoTx) is a developer of novel immunotherapies in cancer and infectious disease. Our unique approach to immunotherapy, based on oncolytic viruses and viral vectors combined with disease-specific peptides, delivers highly adaptable and immunogenic therapeutic vaccination platforms. A spin-out company from the University of Helsinki, Finland, Valo Tx has assembled a talented team of immunotherapy experts, who together with the founding scientists have the necessary expertise to take its patented technology through clinical development and make it available to patients. The management team has a proven track record of developing successful companies from a laboratory idea … 83 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 20 |
![]() | ![]() Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies. Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies. Our innovative technological approach is to target tumors overexpressing matricellular protein thrombospondin-1 (TSP-1). Our long-term vision is to develop personalized immunotherapy approaches combining a proprietary therapeutic peptide targeting TSP-1 (namely TAX2 peptide) and a companion diagnostic kit, which may enable patient stratification for TAX2 therapy eligibility based on the monitoring of circulating TSP-1. immunologie and oncologie 28 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 38 | 18 |
![]() | ![]() NanoMedSyn develops a new delivery platform to create first-in-class drugs by the engineering with patented AMFA vectors NanoMedSyn was born from the fundamental research of its biologist and chemist founders who discovered a breakthrough technology for drug delivery to the lysosomal cell compartment leading to potentiation of therapeutics. This technology, validated at the preclinical level, has a wide range of applications in the fields of oncology, immunity, inflammation or metabolism. NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA. The main application is the engineering of recombinant proteins like antibodies or enzymes for … 155 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 5 |
![]() | ![]() Discovering drugs that create neoantigens NeoPhore, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Generation of cancer neoantigens in tumours can be exploited by the patients’ immune system to overcome natural defence mechanisms in cancer. The Company’s approach targets the DNA mismatch repair (MMR) pathway, which has been proven to promote neoantigen creation and subsequent immunity against numerous cancers. Using these insights, NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore was spun-out of the University of Turin and PhoreMost … 50 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 22 |
![]() | ![]() Development of covalent small molecules to transform the treatment of autoimmune and inflammatory disorders ARTICA Therapeutics and its seasoned team started operatons in 2020 and was supported by pre-Seed financing from BioGeneration Ventures. Artica is dedicated to developing novel small molecule medicines for inflammatory and autoimmune indicatons. Artca is at the forefront of covalent binding technology as well as in label-free cellular-based screening approaches. The unique combinaton of these capabilities allows rapid progression of the best drug candidates that have unprecedented and superior characteristics, creating novel and highly selective therapies for patients with unmet medical need. 21 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 16 |
![]() | ![]() AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine 576 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 1 |
![]() | ![]() Maximizing Immunoassays Performances InfYnity Biomarkers was founded in 2009 in Lyon (France). We are an R&D In-Vitro Diagnostics Company fully dedicated to infectious diseases and immunity. Company Mission: Maximizing Immunoassay Performance i.e. we have the ambition to set new criteria for immunoassays: study the diversity of immune response to provide high-value information instead of the binary response. Our Offer: - High quality, custom-made biomaterial (antigens and antibodies) - RUO Multiplex Immunoassays - Tailored immunobiology services ranging from biomaterial design to biomarker discovery and immunoassay development. Our originality and strength relies on a unique combination of proven skills: Multiplex technology AND … 90 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 6 |
![]() | ![]() Delivering Value Through the Power of Plants Serendip Innovations is a preclinical-stage biotechnology company developing a cutting-edge nanoparticulate delivery platform for active ingredients. We offer co-development partnerships and technology licensing opportunities for applications such as therapeutic and prophylactic vaccines, as well as precision medicine. What sets us apart is the high modularity of our platform, enabling the custom design of a new generation of targeted therapeutics. As a first application, Serendip is addressing the challenges of therapeutic cancer vaccines by transforming its platform into a high-performance immunization system. This system enhances the presentation of tumor antigens and elicits strong anti-tumor … Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 17 | 12 |
![]() | ![]() Empowering Personalized Immunotherapy to Treat Cancer Odimma is a French biotech company with a unique approach in active personalized cancer immunotherapy. Immunotherapy has revolutionized the treatment of many advanced cancers. Despite this amazing achievement, significant clinical benefits are still limited to 10 to 30% of patients. Odimma believes in the future of precision medicine, and leverages recent advances in the field of immuno-oncology to amplify the efficacy of current therapies, improving lives and making each patient unique. By harnessing the ability of the patient’s own immune system to specifically recognize non-self-targets displayed by the tumor, also called neoantigens, Odimma has … 31 similar entities Type: Startup Activities: manufacturing deeptech biotech Technologies: Synthetic Biology | 12 | 6 |
![]() | ![]() IsomAb is taking a different approach to identify, evaluate and develop isoform specific antibodies to treat disease where patients currently have limited or no treatment options. IsomAb is developing isoform specific antibodies and it has identified, using a combined bioinformatics/knowledge-based platform approach, ISM-001 which specifically inhibits the VEGF-A165b isoform of Vascular Endothelial Growth Factor-A (VEGF-A); based on 20 years of research by our two Founders, the evidence shows reducing serum levels of VEGF-A165b is key to ensuring new blood vessel formation in patients with ischemic disease. 44 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 15 |
![]() | ![]() Science for cure. NEOGAP Therapeutics AB is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology. The company was founded in 2016 by Dr. Hans Grönlund. We are located at Therapeutic Immune Design, Centre for Molecular Medicine at Karolinska Institute, Stockholm, Sweden. Our vision is to increase overall survival among patients with cancer by boosting tumour-specific responses of the immune system. Our mission is to become an important player in the battle against cancer by development and commercialisation of our innovative cancer immunotherapy. Biopharmaceutical company, Immunotherapy, and Immuno-oncology 61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 28 |
![]() | ![]() Novel small-molecule drugs in immunology, fibrosis and women health Clinical-stage biotech company founded by serial entrepreneurs and owned by private & institutional investors. Discovery and development of new chemical entities with strong IP and worldwide rights targeting indications with high unmet medical need in immunology, fibrosis and women health. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, Inflammation and autoimmune diseases, IP generation, IBD, Ulcerative Colitis, Crohn's disease, Fibrosis, and Uterine fibroids 252 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 10 |
![]() | ![]() Swedish biotech company exploring reprogramming as the next leap forward in cancer immunotherapy Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard Therapeutics aims to build a pipeline of personalized cancer immunotherapies optimized to each unique patient. Cell Reprogramming, Cancer Immunotherapy, and … 144 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 28 |
![]() | ![]() Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be … 153 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 60 |
![]() | ![]() New therapies for inflammatory disease and cancer by targeting fibroblast immunology Mestag focuses on fibroblast-immune interactions to develop innovative new treatments for inflammatory disease and cancer. Through our unique understanding of fibroblast immunology, we are advancing a pipeline of first-in-class antibody programs and targets for new treatments. Backed by committed leading global investors, world-class founders and a highly experienced leadership team, Mestag offers an exciting, diverse and balanced place to work, with competitive benefits, generous vacation time and the room to grow and develop your career. biotechnology, fibroblasts, oncology, immuno oncology, inflammatory disease, and datascience 60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 54 |
![]() | ![]() Living Immunotherapies Medigene AG (FSE: MDG1) is a leading immuno-oncology platform company dedicated to developing T-cell therapies to effectively eliminate cancer. Its end-to-end technology platform is built on multiple proprietary exclusive product development and product enhancement technologies, and allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering. For more information, please visit www.medigene.com Immunotherapies and T Cell receptors TCR 56 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 94 |
![]() | ![]() Leveraging science and innovation to accelerate the development of next-generation antibody therapeutics. AAX Biotech AB is a biotech company spun out from Karolinska Institutet by co-founders Mats AA Persson and Daniel X Johansson. We specialize in next-generation antibody therapeutics through our two unique and proprietary technologies, SeqitopeTM and Opti-mAbTM, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Our team is made up of highly qualified experts, all with PhDs in relevant fields. Our mission is to innovate and solve unmet needs … 75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 7 |